SEQENSgroup

Seqens has invested over the last 3 years in state-of-the-art analytical tools to optimise the efficiency of the digitisation of its analytical data.

Today the clinical development of new APIs involves not only the synthesis of the active ingredient at laboratory scale but also the generation of an exponential amount of analytical data to characterize the API in terms of quality and purity

Thanks to the implementation of last generation software, we have for example been able to launch the experiments in the morning during the confinement and to control them remotely in Home Office.

Christophe Eychenne-Baron

SEQENS R&D DIRECTOR

More generally, the current health crisis requires an acceleration of development phases, which can only be achieved through a close and powerful link between Pharmaceutical Chemistry and Digitalization, a topic at the heart of Seqens’ strategy.

DISCOVER OUR NEWS

Learn more